Disc Medicine, Inc. (IRON)
Automate Your Wheel Strategy on IRON
With Tiblio's Option Bot, you can configure your own wheel strategy including IRON - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IRON
- Rev/Share 0.0
- Book/Share 17.5353
- PB 4.9748
- Debt/Equity 0.0503
- CurrentRatio 32.1068
- ROIC -0.2622
- MktCap 3032775459.0
- FreeCF/Share -3.8703
- PFCF -22.3729
- PE -21.0153
- Debt/Assets 0.0465
- DivYield 0
- ROE -0.266
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | IRON | Truist | -- | Buy | -- | $86 | July 21, 2025 |
| Resumed | IRON | Morgan Stanley | -- | Overweight | -- | $85 | July 3, 2025 |
| Resumed | IRON | Raymond James | -- | Strong Buy | -- | $89 | June 11, 2025 |
| Initiation | IRON | TD Cowen | -- | Buy | -- | -- | Feb. 27, 2025 |
| Initiation | IRON | Jefferies | -- | Buy | -- | $89 | Oct. 23, 2024 |
| Initiation | IRON | Scotiabank | -- | Sector Outperform | -- | -- | Oct. 16, 2024 |
| Initiation | IRON | Wells Fargo | -- | Overweight | -- | $75 | Aug. 22, 2024 |
News
Does Disc Medicine, Inc. (IRON) Have the Potential to Rally 26.29% as Wall Street Analysts Expect?
Published: October 22, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 26.3% upside potential for Disc Medicine, Inc. (IRON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
Published: October 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
WATERTOWN, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the pricing of the upsized underwritten offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. Disc is selling 2,619,049 shares of common stock and pre-funded warrants to purchase 59,523 shares of common stock and AI DMI LLC (the Selling Stockholder) is selling 297,619 shares …
Read More
Disc Medicine: NDA Submission And CNPV For Bitopertin Further Boost Shareholder Value
Published: October 20, 2025 by: Seeking Alpha
Sentiment: Positive
Disc Medicine receives a "Strong Buy" rating due to significant progress with bitopertin for EPP and XLP treatment. IRON submitted an NDA for bitopertin under Accelerated Approval, supported by positive BEACON and AURORA phase 2 study results showing reduced PPIX and improved QoL. The company earned a rare Commissioner's National Priority Review Voucher (CNPV), potentially expediting FDA review to as little as 1-2 months.
Read More
Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week
Published: October 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
WATERTOWN, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced it will present clinical data as a poster presentation at the upcoming 2025 American Society of Nephrology (ASN) Kidney Week, which will be held in Houston, TX on November 6-9, 2025.
Read More
Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP)
Published: September 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
WATERTOWN, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bitopertin for patients aged 12 years and older with erythropoietic protoporphyria (EPP), including X-linked protoporphyria (XLP). Disc submitted the NDA under the FDA's accelerated approval pathway using reduction of protoporphyrin IX (PPIX) as a surrogate endpoint and requested a Priority Review based on bitopertin's potential to address the …
Read More
Disc Medicine Appoints Nadim Ahmed to its Board of Directors
Published: July 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
WATERTOWN, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Nadim Ahmed to its Board of Directors. Mr. Ahmed is currently the President and Chief Executive Officer of Cullinan Therapeutics.
Read More
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress
Published: May 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
WATERTOWN, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it will present data from multiple programs in its hematology portfolio at the upcoming European Hematology Association (EHA) 2025 Congress, which will be held in Milan, Italy on June 12-15, 2025.
Read More
All You Need to Know About Disc Medicine, Inc. (IRON) Rating Upgrade to Buy
Published: March 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Disc Medicine, Inc. (IRON) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Wall Street Analysts Predict a 68.78% Upside in Disc Medicine, Inc. (IRON): Here's What You Should Know
Published: March 03, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 68.8% upside potential for Disc Medicine, Inc. (IRON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
WATERTOWN, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a recap of recent program and corporate developments.
Read More
Disc Medicine to Participate in Upcoming Investor Conferences
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will present at three upcoming investor conferences:
Read More
Disc Medicine, Inc. (IRON) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Disc Medicine, Inc. (IRON) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Read More
About Disc Medicine, Inc. (IRON)
- IPO Date 2020-08-12
- Website https://www.discmedicine.com
- Industry Biotechnology
- CEO John D. Quisel
- Employees 94